Mineralys Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €671.78M +157.6% €212.46M -422.3% 31.6% +0.57 pp N/A N/A
    (estimated) €260.77M +234.7% -€65.91M -65.0% -25.3% +2.2 pp N/A N/A
    (estimated) €77.92M +704.7% -€188.11M +12.6% -241.4% +15 pp N/A N/A
    (estimated) €9.68M +∞% -€167.07M +9.3% -1,725.4% -17 pp N/A N/A
    (estimated) €0.00 +NaN% -€152.91M +0.2% N/A N/A N/A
    €0.00 +NaN% -€152.64M +147.3% N/A -€142.69M +104.8% N/A
    €0.00 +NaN% -€61.72M +141.3% N/A -€69.68M +177.8% N/A
    €0.00 +NaN% -€25.58M +53.5% N/A -€25.08M +100.7% N/A
    €0.00 +NaN% -€16.66M +466.5% N/A -€12.50M +491.1% N/A
    €0.00 -€2.94M N/A -€2.11M N/A

    Notifications